Company news
Viva Biotech Holdings (HKEX:1873) news
Viva Biotech Holdings news releases on 6ix. Latest, Aug 26, 2026: Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO…
Press releases & updates
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
August 26, 2026
Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
March 30, 2026
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
December 29, 2025
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
December 15, 2025
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
September 29, 2025
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
September 2, 2025
Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth
August 28, 2025
Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
March 28, 2025
Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D
March 27, 2025
Viva Biotech Officially Establishes Boston Branch, Marking another Milestone in Global Expansion
December 12, 2024
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
August 29, 2024
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
March 28, 2024
Viva Biotech Announces 2023 Interim Results Solid Growth in Main Business, Significant Rebound in Profitability
August 30, 2023
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
August 29, 2023
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
June 16, 2023
Viva Biotech Successfully Held The 3rd Annual Partnership Summit
June 23, 2022
Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%
March 28, 2022
Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests
March 18, 2022
Viva Biotech : Announced 2021 Interim Results
August 30, 2021
Viva Biotech : PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES PROPOSED DECLARATION AND PAYMENT OF FINAL DIVIDEND AND NOTICE OF ANNUAL GENERAL MEETING
April 28, 2021
Viva Biotech : CHANGE OF CHIEF FINANCIAL OFFICER
April 25, 2021
Viva Biotech : Announced 2020 Annual Results
March 30, 2021
Viva Biotech : (Re-published for debt holders information) PROFIT WARNING
March 17, 2021
Viva Biotech : COMPLETION OF THE ACQUISITION OF THE ENTIRE EQUITY INTEREST IN SYNTHESIS MED CHEM (HONG KONG) LIMITED INVOLVING ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE
March 5, 2021
Viva Biotech : MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF THE ENTIRE ISSUED SHARE CAPITAL IN SYNTHESIS MED CHEM (HONG KONG) LIMITED
February 25, 2021